Liquid Biopsy Webinar

Daniel Kim, PhD

Assistant Professor, UC Santa Cruz, Baskin School of Engineering

Dr. Kim's laboratory is developing novel RNA technologies for precision health, cancer early detection, and drug discovery. He leads a multidisciplinary team of researchers and computational biologists to investigate the molecular mechanisms and RNA biomarkers of cancer initiation and progression, using cutting-edge genomic and machine learning approaches. Dr. Kim is also an Associate Member of the Stanford Canary Center, working with researchers and clinicians to translate discoveries into clinical applications for improving patient outcomes. As a Research Scholar of the American Cancer Society, Dr. Kim is investigating the cell-free RNA transcriptome in the blood of cancer patients by developing highly sensitive and specific RNA liquid biopsy technology for multi-cancer early detection and the discovery of novel drug targets for RNA medicine.

Nafiseh Jafari, PhD

Chief Science Officer at nRichDX

Dr. Jafari joined nRichDX in January 2020 and has over 10 years experience in life science research. She is a scientific leader with a passion for building and managing high performance teams. Dr. Jafari has managed multimillion dollar development projects leading to the successful creation and launch of multiple products. Immediately prior to joining nRichDX, She was a Project Manager leading cross-functional teams at Abbott Diagnostics. Dr. Jafari holds a B.S. degree in Chemistry from Sharif University of Technology and earned her Ph.D. degree in Biochemistry and Molecular Biology at Western Michigan University.

Dr. Jafari will provide a brief overview of the Revolution Sample Prep System^® for extraction of key liquid biopsy analytes, including cfDNA, cfRNA, cf-Total Nucleic Acid, and CTCs, from biofluids.